its proprietary synDNA(TM) production and ssDNA expression
technology. The company has developed a breakthrough synthetic
process for large-scale production of biologically active DNA that
can be made faster and cleaner than production using traditional
fermentation methods and has developed a novel expression vector
that enables production of therapeutic DNA inside the cell.
CytoGenix currently holds 11 granted patents and about 49
international or US pending patent applications claiming methods
and materials in connection with these platform technologies.
SAFE HARBOR: Except for statements of historical fact, the
statements in this press release are forward-looking. Such
statements are subject to a number of risks and uncertainties that
could cause actual results to differ materially from the statements
made. These factors include, but are not limited to, general
economic conditions, risks associated with the acceptance of new
products, competition, and other factors more fully detailed in the
company's filings with the Securities and Exchange Commission.
Additional information about CytoGenix and its technology can be
found on the website at www.cytogenix.com.
Contact
CytoGenix, Inc., Houston
Media Contact:
Pam Schertz, 713-789-0070
'"/>Page: 1 2 Related medicine technology :1.
CytoGenix Announces Successful Testing of synDNA Vaccine for Avian
Influenza Virus2.
The Past, Present and Future of HLA Typing3.
Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis4.
Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis5.
Inspiration Biopharmaceuticals Presents Data From Hemophilia
Program at International Society On Thrombosis and Haemostasis
(ISTH) Annual Meeting6.
Halozyme Therapeutics Enhanze Technology Large Protein Molecule
Therapeutic Clinical Trial Results Presented at the 34th Annual
Meeting of the Controlled Release Society7.
Generex Biotechnology to Make Presentations At 46th Annual Meeting
of the European Society of Pediatric Endocrinology8.
Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging
Growth Opportunities Conference9.
ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth
Opportunities Conference10.
Accelrys to Present to Investors at C.E. Unterberg Emerging Growth
Opportunities Conference11.
Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth
Conference and Attend Pacific Growth Equities Conference